stockrow
Monday 9 November 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMPCAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024.
- Revenue
- +138.9%
- EPS
- +32.7%
- Free cash flow
- +20.4%
Quarter to September 2026, against a year earlier
4.06
0.34
+9.14%
Follow CAMP
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
59.95 | 60.05 | 64.93 | 94.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(39.06) | (19.96) | (23.26) | 52.54 | |
P/B ratio |
2.98 | 0.00 | 8.27 | 6.93 | |
Price to Tangible BV |
2.98 | 0.00 | 8.27 | 6.93 | |
EV/Sales |
36.42 | 39.39 | 39.54 | 62.84 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.59) | (5.81) | (5.93) | (7.44) | |
EV/FCF |
(7.35) | (5.79) | (5.87) | (7.38) | |
Quick Ratio |
6.31 | 4.55 | 6.01 | 7.15 | |
Current Ratio |
6.42 | 4.70 | 6.15 | 7.35 | |
Net Debt/EBITDA |
9.27 | 6.77 | 7.96 | 8.94 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.06 | 0.05 | 0.04 | |
Operating CF/Net income |
0.28 | 0.38 | 0.60 | (0.16) | |
Capex/Depreciation |
(1.41) | (0.25) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
602.11% | 608.04% | 785.16% | 2,401.44% | |
Selling, General and Administrative Expense of Revenue |
236.65% | 244.07% | 324.96% | 1,369.83% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
106.58% | 108.54% | 113.76% | 330.75% | |
Graham Net Nets |
0.32 | (0.02) | 0.11 | 0.13 | |
Graham Number |
0.00 | 0.77 | 0.00 | 0.00 | |
Earnings Yield |
(49.92%) | (50.27%) | (50.72%) | (41.38%) | |
Free Cash Flow Yield |
(8.27%) | (11.33%) | (10.37%) | (9.01%) | |
Revenue per Share |
0.02 | 0.03 | 0.02 | 0.01 | |
Operating CF per Share |
(0.10) | (0.22) | (0.19) | 0.12 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.22) | (0.19) | 0.12 | |
Cash per Share |
1.59 | 1.50 | 1.73 | 2.06 | |
Shareholders Equity per Share |
1.36 | (0.01) | 0.53 | 0.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.36 | (0.01) | 0.53 | 0.88 | |
Free Cash Flow |
(8.90) | (12.81) | (10.98) | 6.29 | |
Working Capital |
107.67 | 70.89 | 85.57 | 98.58 | |
Capital Expenditures |
(0.74) | (0.13) | — | 0.00 | |
Net Current Asset Value |
100.62 | (4.09) | 27.64 | 43.99 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.39 | 0.07 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.67 | 1.14 | 1.13 | 0.70 | |
Average Assets |
110.20 | 72.35 | 84.12 | 98.06 | |
Average Common Equity |
82.88 | 19.65 | 41.24 | 55.42 |
Columns are period end dates · fundamentals updated 5 Nov 2026